TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)

被引:21
作者
Lee, Jihye [1 ]
Lee, JinAh [1 ]
Kim, Hyeon Ju [1 ]
Ko, Meehyun [1 ]
Jee, Youngmee [2 ]
Kim, Seungtaek [1 ]
机构
[1] Inst Pasteur Korea, Zoonot Virus Lab, Seongnam, South Korea
[2] Inst Pasteur Korea, CEO Off, Seongnam, South Korea
基金
新加坡国家研究基金会;
关键词
COVID-19; RNA-dependent RNA polymerase; SARS-CoV-2; TMPRSS2; variant; IDENTIFICATION; MUTATIONS; VIRUS;
D O I
10.1128/Spectrum.00472-21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative agent of the coronavirus disease 2019 (COVID-19) pandemic, and the development of therapeutic interventions is urgently needed. So far, monoclonal antibodies and drug repositioning are the main methods for drug development, and this effort was partially successful. Since the beginning of the COVID-19 pandemic, the emergence of SARS-CoV-2 variants has been reported in many parts of the world, and the main concern is whether the current vaccines and therapeutics are still effective against these variant viruses. Viral entry and viral RNA-dependent RNA polymerase (RdRp) are the main targets of current drug development; therefore, the inhibitory effects of transmembrane serine protease 2 (TMPRSS2) and RdRp inhibitors were compared among the early SARS-CoV-2 isolate (lineage A) and the two recent variants (lineage 8.1.1.7 and lineage 8.1351) identified in the United Kingdom and South Africa, respectively. Our in vitro analysis of viral replication showed that the drugs targeting TMPRSS2 and RdRp are equally effective against the two variants of concern. IMPORTANCE The COVID-19 pandemic is causing unprecedented global problems in both public health and human society. While some vaccines and monoclonal antibodies were successfully developed very quickly and are currently being used, numerous variants of the causative SARS-CoV-2 are emerging and threatening the efficacy of vaccines and monoclonal antibodies. In order to respond to this challenge, we assessed antiviral efficacy of small-molecule inhibitors that are being developed for treatment of COVID-19 and found that they are still very effective against the SARS-CoV-2 variants. Since most small-molecule inhibitors target viral or host factors other than the mutated sequence of the viral spike protein, they are expected to be potent control measures against the COVID-19 pandemic.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 23 条
[1]   Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance [J].
Agostini, Maria L. ;
Pruijssers, Andrea J. ;
Chappell, James D. ;
Gribble, Jennifer ;
Lu, Xiaotao ;
Andres, Erica L. ;
Bluemling, Gregory R. ;
Lockwood, Mark A. ;
Sheahan, Timothy P. ;
Sims, Amy C. ;
Natchus, Michael G. ;
Saindane, Manohar ;
Kolykhalov, Alexander A. ;
Painter, George R. ;
Baric, Ralph S. ;
Denison, Mark R. .
JOURNAL OF VIROLOGY, 2019, 93 (24)
[2]  
[Anonymous], 2020, BIORXIV, DOI DOI 10.1101/2020.01.22.914952
[3]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[4]   SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 [J].
Chen, Peter ;
Nirula, Ajay ;
Heller, Barry ;
Gottlieb, Robert L. ;
Boscia, Joseph ;
Morris, Jason ;
Huhn, Gregory ;
Cardona, Jose ;
Mocherla, Bharat ;
Stosor, Valentina ;
Shawa, Imad ;
Adams, Andrew C. ;
Van Naarden, Jacob ;
Custer, Kenneth L. ;
Shen, Lei ;
Durante, Michael ;
Oakley, Gerard ;
Schade, Andrew E. ;
Sabo, Janelle ;
Patel, Dipak R. ;
Klekotka, Paul ;
Skovronsky, Daniel M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (03) :229-237
[5]   SARS-CoV-2 variants and ending the COVID-19 pandemic [J].
Fontanet, Arnaud ;
Autran, Brigitte ;
Lina, Bruno ;
Kieny, Marie Paule ;
Karim, Salim S. Abdool ;
Sridhar, Devi .
LANCET, 2021, 397 (10278) :952-954
[6]   Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies [J].
Greaney, Allison J. ;
Loes, Andrea N. ;
Crawford, Katharine H. D. ;
Starr, Tyler N. ;
Malone, Keara D. ;
Chu, Helen Y. ;
Bloom, Jesse D. .
CELL HOST & MICROBE, 2021, 29 (03) :463-+
[7]   SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].
Hoffmann, Markus ;
Kleine-Weber, Hannah ;
Schroeder, Simon ;
Krueger, Nadine ;
Herrler, Tanja ;
Erichsen, Sandra ;
Schiergens, Tobias S. ;
Herrler, Georg ;
Wu, Nai-Huei ;
Nitsche, Andreas ;
Mueller, Marcel A. ;
Drosten, Christian ;
Poehlmann, Stefan .
CELL, 2020, 181 (02) :271-+
[8]   Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 [J].
Hoffmann, Markus ;
Schroeder, Simon ;
Kleine-Weber, Hannah ;
Mueller, Marcel A. ;
Drosten, Christian ;
Poehlmann, Stefan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
[9]   Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs [J].
Jeon, Sangeun ;
Ko, Meehyun ;
Lee, Jihye ;
Choi, Inhee ;
Byun, Soo Young ;
Park, Soonju ;
Shum, David ;
Kim, Seungtaek .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
[10]   Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells [J].
Ko, Meehyun ;
Jeon, Sangeun ;
Ryu, Wang-Shick ;
Kim, Seungtaek .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (03) :1403-1408